<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE collection SYSTEM "BioC.dtd"><collection><source>BioC-API</source><date>20250207</date><key>collection.key</key><document><id>10417183</id><infon key="license">CC BY</infon><passage><infon key="alt-title">Li et al.</infon><infon key="article-id_doi">10.1002/cam4.6130</infon><infon key="article-id_other">CAM4-2023-03-1009.R1</infon><infon key="article-id_pmc">10417183</infon><infon key="article-id_pmid">37288833</infon><infon key="article-id_publisher-id">CAM46130</infon><infon key="fn">Cheng Hu contributed equally to this work.</infon><infon key="fpage">14949</infon><infon key="issue">14</infon><infon key="kwd">ALKâpositive (ALKâP) EGFRâmutant (EGFRâM) malignant pleural effusion (MPE) nonâsmallâcell lung cancer (NSCLC) overall survival (OS) thoracic tumor radiotherapy</infon><infon key="license">This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</infon><infon key="lpage">14959</infon><infon key="name_0">surname:Li;given-names:Qingsong</infon><infon key="name_1">surname:Hu;given-names:Cheng</infon><infon key="name_2">surname:Su;given-names:Shengfa</infon><infon key="name_3">surname:Ma;given-names:Zhu</infon><infon key="name_4">surname:Geng;given-names:Yichao</infon><infon key="name_5">surname:Hu;given-names:Yinxiang</infon><infon key="name_6">surname:Jin;given-names:Haijie</infon><infon key="name_7">surname:Li;given-names:Huiqin</infon><infon key="name_8">surname:Lu;given-names:Bing</infon><infon key="notes">

, , , et al. . . ;:â. doi:

</infon><infon key="pub-id_doi">10.1002/cam4.6130</infon><infon key="pub-id_pmid">37288833</infon><infon key="section_type">TITLE</infon><infon key="source">Cancer Med</infon><infon key="type">front</infon><infon key="volume">12</infon><infon key="year">2023</infon><offset>0</offset><text>Impact of thoracic tumor radiotherapy on survival in nonâsmallâcell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>179</offset><text>Abstract</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>188</offset><text>Background</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>199</offset><text>EGFRâmutant (EGFRâM) and ALKâpositive (ALKâP)are common in malignant pleural effusion (MPE) with metastatic nonâsmallâcell lung cancer (NSCLC) (MPEâNSCLC). The impact of thoracic tumor radiotherapy on survival in such patients remains unclear. We aimed to investigate whether thoracic tumor radiotherapy could improve overall survival (OS) in such patients.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>571</offset><text>Methods</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>579</offset><text>According to whether or not patients accepted thoracic tumor radiotherapy, 148 patients with EGFRâM or ALKâP MPEâNSCLC treated with targeted therapy were classified into two groups: DT group without thoracic tumor radiotherapy and DRT group with thoracic tumor radiotherapy. Propensity score matching (PSM) was performed to balance clinical baseline characteristics. Overall survival was analyzed by KaplanâMeier, compared by logârank test, and evaluated using Cox proportional hazards model.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1082</offset><text>Results</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1090</offset><text>Median survival time (MST) was 25âmonths versus 17âmonths in the DRT group and DT group. The OS rates at 1, 2, 3, 5âyears in the DRT group and DT group were 75.0%, 52.8%, 26.8%, 11.1% and 64.5%, 28.4%, 9.2%, 1.8%, respectively (Ï2â=â12.028, pâ=â0.001). Compared with DT group, the DRT group still had better survival after PSM (pâ=â0.007). Before and after PSM, factors associated with better OS through multivariable analysis were that thoracic tumor radiotherapy, radiotherapy, N0â2, and ALKâTKIs. Grades 4â5 radiation toxicities were not observed in patients; 8 (11.6%) and 7 (10.1%) out of the DRT group suffered from Grade 3 radiation esophagitis and radiation pneumonitis, respectively.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1808</offset><text>Conclusion</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1819</offset><text>Our results for EGFRâM or ALKâP MPEâNSCLC showed that thoracic tumor radiotherapy may be crucial factor in improving OS with acceptable toxicities. Potential biases should not be neglected: Further randomized controlled trials are necessary to confirm this result.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>2090</offset><text>INTRODUCTION</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2103</offset><text>Malignant pleural effusion (MPE) is common in patients with advanced stage of all kinds of caners, the most common of which is lung cancer. Nonâsmallâcell lung cancer (NSCLC, rate 86%) is the dominant pathological type. Malignant pleural effusion is related to a worse prognosis and a decrease in quality of life. According to the guidelines of the National Comprehensive Cancer Network (NCCN) and other authoritative guidelines, treatment for NSCLC with MPE (MPEâNSCLC) mainly include two goals: The first goal is to control all involving lesions with systemic treatment and the second is to improve quality of life through the local treatment of MPE.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2762</offset><text>Systemic treatment for stage IV NSCLC has entered the era of precision therapy, including chemotherapy, targeted therapy, and immunotherapy. Tyrosine kinase inhibitors (TKIs) can achieve an excellent therapeutic response in NSCLC with positive mutations in driver Genes and significantly improve progressionâfree survival (PFS). However, disease progression is an inevitable fatal flaw of targeted therapy and occurs mainly within 2âyears. Suchit H. Patel et al. and AlâHalabi H et al. found that the predominant failure in EGFRâmutant (EGFRâM)NSCLC without MPE is in the initial involved lesions (Rate, 79.6â82.4%). Multiple studies have demonstrated that local therapies, such as radiotherapy, can significantly increase progressionâfree survival (PFS) and overall survival (OS).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3558</offset><text>However, all of the above studies excluded patients with MPEâNSCLC. We aimed to investigate whether thoracic tumor radiotherapy could improve OS in such patients and to provide evidence for further prospective clinical trials.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>3787</offset><text>MATERIALS AND METHODS</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>3809</offset><text>Patients</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>3818</offset><text>A retrospective study was conducted on patients with EGFRâM or anaplastic lymphoma kinaseâpositive (ALKâP) NSCLC who had MPE from January 2010 to December 2020 at Affiliated Cancer Hospital of Guizhou Medical University (American Joint Committee on Cancer staging system 7th edition). We searched for potential patients in the electronic medical records system by several keywords: targeted drugs available in our hospital, including gefitinib, icotinib, erlotinib, osimertinib, crizotinib, and alectinib. The potential patients who met the following criteria were enrolled: (1) histologically or cytologically confirmed MPEâNSCLC and molecular testing confirmed EGFRâM or ALKâP; (2) treated with targeted therapy; (3) age â¥18âyears old; (4) without history of thoracic tumor radiotherapy or/and thoracic surgery; (5) without history of malignancy or/and other concomitant malignancy; (6) MPE controlled by the medical intervention (systemic treatment, nâ=â41; systemic treatment plus Intrathoracic chemotherapy, nâ=â107).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4865</offset><text>Through the electronic medical records and the department of epidemiology, we acquired patients characteristics including age, sex, Karnofsky performance status (KPS), pathological type, TNM status, positive mutations, metastasis status, and subsequent treatment. The data of positive mutations were inputted according to electronic medical records of our hospital. This retrospective study was approved by the ethics committee of the affiliated cancer Hospital of Guizhou medical university.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5358</offset><text>Depending on whether or not patients accepted thoracic tumor radiotherapy, patients were classified into two groups: the DT group without thoracic tumor radiotherapy (primary tumor+lymph nodes) and the DRT group with thoracic tumor radiotherapy.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5604</offset><text>Radiotherapy</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>5617</offset><text>Thoracic tumor radiotherapy</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5645</offset><text>Thoracic tumor radiotherapy was not coercive for MPEâNSCLC, but it was performed when MPE was under control and the patient had signed an informed consent form. The treating radiotherapist made the radiotherapy regime. The prescribed dose was to be at least 30âGy and given according to the tolerance of the organ at risk. Seventyâtwo patients received external beam radiation therapy (EBRT) for thoracic tumor (30Gyââ¤âdoseâ&lt;â45Gy, nâ=â6; 45Gyââ¤âdose &lt;54âGy, nâ=â16; 54Gyââ¤âdose â¤â63Gy, nâ=â50). Radiotherapy toxicities were assessed and graded in accordance with Common Terminology Criteria for Adverse Events (CTCAE 4.0).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>6315</offset><text>Metastases radiotherapy</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6339</offset><text>Metastatic radiotherapy depended on clinical need, such as brain metastasis, bone metastasis with moderateâsevere pain or risk of fracture, and vertebral metastasis with risk of compressive myelopathy . Brain metastases radiotherapy included whole brain radiotherapy (WBRT) (30Gy/10 fractions or 40Gy/20 fractions), simultaneous integrated boost intensityâmodulated radiotherapy (SIBâIMRT) (Boost, 47â48Gy/10â12 fractions, WBRT 30Gy/10â12 fractions), and fractionated stereotactic radiotherapy (FSRT) (50Gy/10fractions). Bone metastases radiotherapy was given in 3Gy per fraction (once a day, 5âdays a week, total dose 30â45âGy).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6987</offset><text>Statistical analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7008</offset><text>The study employed SPSS software (version 26.0) for statistical analysis. Pearson's chiâsquared or Fisher's exact test was used to assess baseline characteristics. Overall survival was defined as the period from start date of treatment (radiotherapy execution date for 31 patients with rescue radiation and start date of any treatment for the remaining patients) to the last followâup date or death from any cause. Propensity score matching (PSM, ratio 1:1, match toleranceâ=â0.1) was performed to minimize the impact of potential confounding factors. The PSM was calculated using logistic regression based on 14 pretherapy factors (age, sex, histology, smoking status, KPS, T stage, N stage, metastasis status [MPE only vs. MPE plus other metastases], involving organ (â¤3 vs. &gt;3) bone metastases, brain metastases, lung metastases, liver metastases, and the positive mutation types [EGFR vs. ALK]), and one therapy factor (systematic chemotherapy). These factors may affect survival. Overall survival was analyzed by KaplanâMeier, compared by logârank test, and evaluated using Cox proportional hazards model. All statistical tests were twoâsided, and pâvalues &lt;0.05 were considered statistically significant.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>8237</offset><text>RESULTS</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>8245</offset><text>Patient characteristics</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>8269</offset><text>From January 2010 to December 2020, a total of 148 patients were statistically analyzed. Of 148 patients, 72 accepted thoracic tumor radiotherapy (DRT group, FigureÂ 1). Clinical characteristics are presented in TableÂ 1. Males accounted for 48.6% of the total; the median age at MPE diagnosis was 56âyears (age â¤70âyears in 124 patients), and the KPS of about twoâthirds of patients was less than or equal to 80. T stage distribution at diagnosis was T1â2(nâ=â46, 31%) and T3â4(nâ=â102, 69%), the corresponding N stage was N0â2(nâ=â65, 44%) and (nâ=â83, 56%). At initial diagnosis, the top three metastatic organs were bone (43.9%), lung (28.4%), and brain (21.6%). The two groups were no significant difference concerning sex, age, smoking status, KPS, T stage, N stage, metastasis status (MPE only vs MPE plus other metastases), involving organ (â¤3 vs. &gt;3), and positive mutation types (EGFRâM vs. ALKâP). Most patients (nâ=â107, 72.3%) underwent oneâ to fourâcycle intrathoracic chemotherapy (median: 1âcycle) in the initial treatment. Sixtyâfour patients underwent systematic chemotherapy (nâ=â47, initial treatment; nâ=â15, disease progression). Disease progression was observed in 59 patients in DT group and 26 patients undergone local failure TableÂ S1.</text></passage><passage><infon key="file">CAM4-12-14949-g002.jpg</infon><infon key="id">cam46130-fig-0001</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>9588</offset><text>Flowchart of patient cohort.</text></passage><passage><infon key="file">cam46130-tbl-0001.xml</infon><infon key="id">cam46130-tbl-0001</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>9617</offset><text>Clinical characteristics in 148 patients.</text></passage><passage><infon key="file">cam46130-tbl-0001.xml</infon><infon key="id">cam46130-tbl-0001</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;thead valign=&quot;bottom&quot;&gt;&lt;tr style=&quot;border-bottom:solid 1px #000000&quot;&gt;&lt;th align=&quot;left&quot; rowspan=&quot;2&quot; colspan=&quot;2&quot; style=&quot;border-bottom:solid 1px #000000&quot; valign=&quot;bottom&quot;/&gt;&lt;th align=&quot;left&quot; style=&quot;border-bottom:solid 1px #000000&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;All&lt;/th&gt;&lt;th align=&quot;left&quot; style=&quot;border-bottom:solid 1px #000000&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;DRT group&lt;/th&gt;&lt;th align=&quot;left&quot; style=&quot;border-bottom:solid 1px #000000&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;DT group&lt;/th&gt;&lt;th align=&quot;left&quot; rowspan=&quot;2&quot; style=&quot;border-bottom:solid 1px #000000&quot; valign=&quot;bottom&quot; colspan=&quot;1&quot;&gt;Ï&lt;sup&gt;2&lt;/sup&gt;
&lt;/th&gt;&lt;th align=&quot;left&quot; rowspan=&quot;2&quot; style=&quot;border-bottom:solid 1px #000000&quot; valign=&quot;bottom&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;p&lt;/italic&gt; value&lt;/th&gt;&lt;/tr&gt;&lt;tr style=&quot;border-bottom:solid 1px #000000&quot;&gt;&lt;th align=&quot;left&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;(&lt;italic toggle=&quot;yes&quot;&gt;n&lt;/italic&gt;â=â148)&lt;/th&gt;&lt;th align=&quot;left&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;(&lt;italic toggle=&quot;yes&quot;&gt;n&lt;/italic&gt;â=â72)&lt;/th&gt;&lt;th align=&quot;left&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;(&lt;italic toggle=&quot;yes&quot;&gt;n&lt;/italic&gt;â=â76)&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody valign=&quot;top&quot;&gt;&lt;tr&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;Sex&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;72&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;35&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;37&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.000&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;&amp;gt;0.999&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Female&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;76&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;37&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;39&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;Age (years)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;â¤56&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;76&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;34&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;2.736&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.104&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;gt;56&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;72&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;30&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;Histology (squamous carcinoma)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;â&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.235&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;146&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;70&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;76&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;Smoking&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;54&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;27&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;27&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.062&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.865&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;94&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;45&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;49&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;KPS&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;â¤80&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;95&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;46&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;49&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.06&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;&amp;gt;0.999&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;90â100&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;53&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;26&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;27&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;T stage&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;â¤2&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;46&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;22&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;24&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.018&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;&amp;gt;0.999&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3â4&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;102&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;50&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;52&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;N stage&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;â¤2&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;65&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;34&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;31&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.621&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.508&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;83&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;38&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;45&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;Metastatic status&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;MPE only&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;41&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;23&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;18&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;1.260&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.276&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;MPEâ+âother metastasis&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;107&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;49&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;58&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;7&quot; valign=&quot;top&quot; rowspan=&quot;1&quot;&gt;Other metastases&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;Bone&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;65&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;28&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;37&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;1.440&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.250&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;83&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;44&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;39&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;Brain&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;32&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;15&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;17&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.051&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.844&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;116&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;57&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;59&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;Lung&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;16&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;26&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;2.614&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.144&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;106&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;56&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;50&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;Liver&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;13&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;3.731&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.080&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;135&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;69&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;66&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;Adrenal&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;â&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;&amp;gt;0.999&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;138&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;67&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;71&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;Other&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;25&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;13&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.135&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.827&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;123&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;59&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;64&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;Involving organâ¤3&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;53&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;27&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;26&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.174&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.733&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;95&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;45&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;50&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;Positive mutation types&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;EGFRâM&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;127&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;62&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;65&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.010&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;&amp;gt;0.999&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ALKâP&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;21&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;Systematic chemotherapy&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;64&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;22&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;13.009&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;84&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;30&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;54&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;EGFRâTKIs&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Gefitinib&lt;sup&gt;1&lt;/sup&gt;/Icotinib&lt;sup&gt;2&lt;/sup&gt;/Erlotinib&lt;sup&gt;3&lt;/sup&gt;
&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;110&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;53&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;57&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.133&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;0.797&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Osimertinib after 1/2/3&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;17&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;ALKâTKIs&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Crizotinib&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;17&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;â&lt;/td&gt;&lt;td rowspan=&quot;2&quot; align=&quot;left&quot; valign=&quot;top&quot; colspan=&quot;1&quot;&gt;&amp;gt;0.999&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Alectinib/Alectinib after Crizotinib&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;7&quot; valign=&quot;top&quot; rowspan=&quot;1&quot;&gt;Radiotherapy&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style=&quot;padding-left:10%&quot; align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Thoracic tumor&lt;xref rid=&quot;cam46130-note-0004&quot; ref-type=&quot;table-fn&quot;&gt;
&lt;sup&gt;b&lt;/sup&gt;
&lt;/xref&gt;
&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;EBRT (30â63âGy)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;72&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style=&quot;padding-left:10%&quot; align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Metastases&lt;xref rid=&quot;cam46130-note-0003&quot; ref-type=&quot;table-fn&quot;&gt;
&lt;sup&gt;a&lt;/sup&gt;
&lt;/xref&gt;
&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;56&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style=&quot;padding-left:10%&quot; align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Brain&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;33&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;FSRT (50Gy/10f)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;18&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wholeâbrain irradiation&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;SIBâIMRT&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style=&quot;padding-left:10%&quot; align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Bone&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;EBRT&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;14&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style=&quot;padding-left:10%&quot; align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Other metastases&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;EBRT&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>9659</offset><text>	All	DRT group	DT group	Ï2	p value	 	(nâ=â148)	(nâ=â72)	(nâ=â76)	 	Sex	Male	72	35	37	0.000	&gt;0.999	 	Female	76	37	39	 	Age (years)	â¤56	76	42	34	2.736	0.104	 	&gt;56	72	30	42	 	Histology (squamous carcinoma)	Yes	2	2	0	â	0.235	 	No	146	70	76	 	Smoking	Yes	54	27	27	0.062	0.865	 	No	94	45	49	 	KPS	â¤80	95	46	49	0.06	&gt;0.999	 	90â100	53	26	27	 	T stage	â¤2	46	22	24	0.018	&gt;0.999	 	3â4	102	50	52	 	N stage	â¤2	65	34	31	0.621	0.508	 	3	83	38	45	 	Metastatic status	MPE only	41	23	18	1.260	0.276	 	MPEâ+âother metastasis	107	49	58	 	Other metastases	 	Bone	Yes	65	28	37	1.440	0.250	 	No	83	44	39	 	Brain	Yes	32	15	17	0.051	0.844	 	No	116	57	59	 	Lung	Yes	42	16	26	2.614	0.144	 	No	106	56	50	 	Liver	Yes	13	3	10	3.731	0.080	 	No	135	69	66	 	Adrenal	Yes	10	5	5	â	&gt;0.999	 	No	138	67	71	 	Other	Yes	25	13	12	0.135	0.827	 	No	123	59	64	 	Involving organâ¤3	Yes	53	27	26	0.174	0.733	 	No	95	45	50	 	Positive mutation types	EGFRâM	127	62	65	0.010	&gt;0.999	 	ALKâP	21	10	11	 	Systematic chemotherapy	Yes	64	42	22	13.009	&lt;0.001	 	No	84	30	54	 	EGFRâTKIs	Gefitinib1/Icotinib2/Erlotinib3	110	53	57	0.133	0.797	 	Osimertinib after 1/2/3	17	9	8	 	ALKâTKIs	Crizotinib	17	8	9	â	&gt;0.999	 	Alectinib/Alectinib after Crizotinib	4	2	2	 	Radiotherapy	 	Thoracic tumorb	EBRT (30â63âGy)	72					 	Metastasesa		56					 	Brain		33					 		FSRT (50Gy/10f)	18					 		Wholeâbrain irradiation	8					 		SIBâIMRT	7					 	Bone	EBRT	14					 	Other metastases	EBRT	9					 	</text></passage><passage><infon key="file">cam46130-tbl-0001.xml</infon><infon key="id">cam46130-tbl-0001</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>11133</offset><text>Abbreviations: FSRT, fractionated stereotatic radiotherapy; KPS, Karnofsky performance status; SIBâIMRT, Simultaneous Integrated Boost intensity modulated radiation therapy.</text></passage><passage><infon key="file">cam46130-tbl-0001.xml</infon><infon key="id">cam46130-tbl-0001</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>11309</offset><text>Nine patients treated with other site radiotherapy (bone in 6 patients, other metastasis in 3 patients).</text></passage><passage><infon key="file">cam46130-tbl-0001.xml</infon><infon key="id">cam46130-tbl-0001</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>11414</offset><text>Thoracic tumor, primary tumor+lymph nodes.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>11457</offset><text>Radiotherapy</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>11470</offset><text>Of the 148 patients, 29.7% (44 patients) underwent radiotherapy at both thoracic tumor radiotherapy and metastasis sites, 27.0% (40 patients) at either thoracic tumor or metastasis sites, but 43.3% (64 patients) did not receive any radiotherapy (TableÂ 1). Thoracic tumor radiotherapy and targeted therapy were performed concurrently in 41 patients (concurrent chemotherapy in 31 patients). Of the 72 patients in the DRT group, 73.6% (nâ=â53) received thoracic tumor radiotherapy in the initial treatment and 26.4% (nâ=â19) received rescue radiation after disease progression. In the DT group, 15.8% (nâ=â12) received rescue radiation after disease progression.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>12144</offset><text>Survival outcomes</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12162</offset><text>The last followâup was in November 2022, with median followâup of 22âmonths. At last followâup, 126 of 148 cases died. Median survival time (MST)of 148 patients was 18.9âmonths (95% CI: 15.6â22.2), and 1âyear, 2âyears, 3âyears, and 5âyears of OS rates were 69.6%, 10.3%, 18.0%, and 6.7%. The OS rates at 1, 2, 3, 5âyears of the DRT group and DT group were 75.0%, 52.8%, 26.8%, 11.1% and 64.5%, 28.4%, 9.2%, 1.8%, respectively; corresponding MST was 25âmonths in the DRT group and 17âmonths in the DT group (Ï2â=â12.028, pâ=â0.001) (FigureÂ 2). Radiotherapy at any sites significantly improved OS (nâ=â84, MST 22.0 vs. 17.5âmonths, Ï2â=â4.904, pâ=â0.027).</text></passage><passage><infon key="file">CAM4-12-14949-g003.jpg</infon><infon key="id">cam46130-fig-0002</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>12867</offset><text>Overall survival outcomes in DRT and DT groups.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>12915</offset><text> OS analysis after PSM </text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12939</offset><text>Following the PSM, 56 pairs were successfully matched. After PSM, the baseline characteristics were shown in TableÂ S2. The survival outcomes were in keeping with that before PSM. The OS rates at 1, 2, 3, 5âyears of the DRT group and DT group were 73.2%, 50.0%, 26.7%, 10.8% and 62.5%, 29.7%, 10.7%, 2.1%, respectively. The MST was 23âmonths and 17.1âmonths in the DRT group and DT group (Ï2â=â7.250, pâ=â0.007) (FigureÂ 3).</text></passage><passage><infon key="file">CAM4-12-14949-g001.jpg</infon><infon key="id">cam46130-fig-0003</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>13379</offset><text>Overall survival outcomes in DRT and DT groups after PSM.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>13437</offset><text>Univariate and multivariate analysis</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>13474</offset><text>Univariate analysis showed that T1â2 stage, N0â2 stage, MPE only, No brain metastases, No liver metastases, Involving organ â¤3, ALKâTKIs, radiotherapy, and thoracic tumor radiotherapy were significantly related with more excellent OS (TableÂ 2). Multivariate analysis revealed that thoracic tumor radiotherapy, radiotherapy, T1â2, N0â2, and ALKâTKIs were independent predictors of better OS. In multivariate analysis after PSM, thoracic tumor radiotherapy, radiotherapy, N0â2, and ALKâ TKIs predicted longer OS (TableÂ 3).</text></passage><passage><infon key="file">cam46130-tbl-0002.xml</infon><infon key="id">cam46130-tbl-0002</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>14015</offset><text>Univariable analysis on OS before and after PSM.</text></passage><passage><infon key="file">cam46130-tbl-0002.xml</infon><infon key="id">cam46130-tbl-0002</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;thead valign=&quot;bottom&quot;&gt;&lt;tr style=&quot;border-bottom:solid 1px #000000&quot;&gt;&lt;th align=&quot;left&quot; rowspan=&quot;2&quot; colspan=&quot;2&quot; style=&quot;border-bottom:solid 1px #000000&quot; valign=&quot;bottom&quot;&gt;Variable&lt;/th&gt;&lt;th align=&quot;left&quot; colspan=&quot;3&quot; style=&quot;border-bottom:solid 1px #000000&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot;&gt;Before PSM (=148)&lt;/th&gt;&lt;th align=&quot;left&quot; colspan=&quot;3&quot; style=&quot;border-bottom:solid 1px #000000&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot;&gt;After PSM (&lt;italic toggle=&quot;yes&quot;&gt;n&lt;/italic&gt;â=â112)&lt;/th&gt;&lt;/tr&gt;&lt;tr style=&quot;border-bottom:solid 1px #000000&quot;&gt;&lt;th align=&quot;left&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;HR&lt;/th&gt;&lt;th align=&quot;left&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;95% CI&lt;/th&gt;&lt;th align=&quot;left&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;p&lt;/th&gt;&lt;th align=&quot;left&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;HR&lt;/th&gt;&lt;th align=&quot;left&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;95% CI&lt;/th&gt;&lt;th align=&quot;left&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;p&lt;/italic&gt;
&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody valign=&quot;top&quot;&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Sex&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male vs. Female&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.95&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.67â1.34&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.758&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.06&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.71â1.59&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.786&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Age&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;â¤56 vs. &amp;gt;56&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.86&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.60â1.22&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.384&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.87&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.58â1.31&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.511&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Smoking&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes vs. No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.15&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.80â1.65&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.450&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.19&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.79â1.80&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.396&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;KPS&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;â¤80 vs. &amp;gt;80&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.33&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.92â1.92&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.130&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.21&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.80â1.83&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.357&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;T status&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;T&lt;sub&gt;1â2&lt;/sub&gt; vs. T&lt;sub&gt;3â4&lt;/sub&gt;
&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.58&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.39â0.87&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.008&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.63&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.40â0.98&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.039&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;N status&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;N&lt;sub&gt;0â2&lt;/sub&gt; vs. N&lt;sub&gt;3&lt;/sub&gt;
&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.67&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.47â0.97&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.032&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.59&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.39â0.89&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.012&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;MPE only&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes vs. No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.59&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.40â0.89&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.012&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.62&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.39â0.96&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.033&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Bone metastases&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes vs. No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.33&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.93â1.89&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.117&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.26&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.84â1.89&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.267&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Brain metastases&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes vs. No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.54&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.00â2.35&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.046&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.42&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.87â2.34&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.164&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Lung metastases&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes vs. No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.32&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.90â1.95&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.157&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.21&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.78â1.88&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.391&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Liver metastases&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes vs. No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.98&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.09â3.62&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.026&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.02&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.88â4.64&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.099&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adrenal metastases&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes vs. No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.94&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.48â1.86&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.867&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.98&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.45â2.13&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.963&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Other metastases&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes vs. No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.90&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.56â1.46&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.678&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.0.06&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.63â1.80&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.819&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Involving organ&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;â¤3 vs. &amp;gt;3&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.67&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.46â0.97&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.014&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.64&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.42â0.97&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.037&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;TKIs&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;EGFR vs. ALK&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.22&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.24â3.95&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.007&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.79&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.93â3.45&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.084&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Systematic chemotherapy&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes vs. No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.81&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.57â1.15&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.238&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.02&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.69â1.54&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.902&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;thoracic radiotherapy&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes vs. No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.54&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.38â0.77&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.001&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.58&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.38â0.87&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.008&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Radiotherapy&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes vs. No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.67&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.47â0.96&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.029&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.73&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.49â1.09&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.123&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Metastases radiotherapy&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes vs. No&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.85&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.59â1.23&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.392&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.81&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.53â1.24&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.332&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>14064</offset><text>Variable	Before PSM (=148)	After PSM (nâ=â112)	 	HR	95% CI	p	HR	95% CI	p	 	Sex	Male vs. Female	0.95	0.67â1.34	0.758	1.06	0.71â1.59	0.786	 	Age	â¤56 vs. &gt;56	0.86	0.60â1.22	0.384	0.87	0.58â1.31	0.511	 	Smoking	Yes vs. No	1.15	0.80â1.65	0.450	1.19	0.79â1.80	0.396	 	KPS	â¤80 vs. &gt;80	1.33	0.92â1.92	0.130	1.21	0.80â1.83	0.357	 	T status	T1â2 vs. T3â4	0.58	0.39â0.87	0.008	0.63	0.40â0.98	0.039	 	N status	N0â2 vs. N3	0.67	0.47â0.97	0.032	0.59	0.39â0.89	0.012	 	MPE only	Yes vs. No	0.59	0.40â0.89	0.012	0.62	0.39â0.96	0.033	 	Bone metastases	Yes vs. No	1.33	0.93â1.89	0.117	1.26	0.84â1.89	0.267	 	Brain metastases	Yes vs. No	1.54	1.00â2.35	0.046	1.42	0.87â2.34	0.164	 	Lung metastases	Yes vs. No	1.32	0.90â1.95	0.157	1.21	0.78â1.88	0.391	 	Liver metastases	Yes vs. No	1.98	1.09â3.62	0.026	2.02	0.88â4.64	0.099	 	Adrenal metastases	Yes vs. No	0.94	0.48â1.86	0.867	0.98	0.45â2.13	0.963	 	Other metastases	Yes vs. No	0.90	0.56â1.46	0.678	1.0.06	0.63â1.80	0.819	 	Involving organ	â¤3 vs. &gt;3	0.67	0.46â0.97	0.014	0.64	0.42â0.97	0.037	 	TKIs	EGFR vs. ALK	2.22	1.24â3.95	0.007	1.79	0.93â3.45	0.084	 	Systematic chemotherapy	Yes vs. No	0.81	0.57â1.15	0.238	1.02	0.69â1.54	0.902	 	thoracic radiotherapy	Yes vs. No	0.54	0.38â0.77	0.001	0.58	0.38â0.87	0.008	 	Radiotherapy	Yes vs. No	0.67	0.47â0.96	0.029	0.73	0.49â1.09	0.123	 	Metastases radiotherapy	Yes vs. No	0.85	0.59â1.23	0.392	0.81	0.53â1.24	0.332	 	</text></passage><passage><infon key="file">cam46130-tbl-0002.xml</infon><infon key="id">cam46130-tbl-0002</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>15544</offset><text>Abbreviations: CI, confidence interval; HR, hazard ratio; PSM, propensity score matching.</text></passage><passage><infon key="file">cam46130-tbl-0003.xml</infon><infon key="id">cam46130-tbl-0003</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>15634</offset><text>Multivariate analysis of overall survival.</text></passage><passage><infon key="file">cam46130-tbl-0003.xml</infon><infon key="id">cam46130-tbl-0003</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;col align=&quot;left&quot; span=&quot;1&quot;/&gt;&lt;thead valign=&quot;bottom&quot;&gt;&lt;tr style=&quot;border-bottom:solid 1px #000000&quot;&gt;&lt;th align=&quot;left&quot; rowspan=&quot;2&quot; style=&quot;border-bottom:solid 1px #000000&quot; valign=&quot;bottom&quot; colspan=&quot;1&quot;&gt;Variable&lt;/th&gt;&lt;th align=&quot;left&quot; colspan=&quot;3&quot; style=&quot;border-bottom:solid 1px #000000&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot;&gt;Before PSM&lt;/th&gt;&lt;th align=&quot;left&quot; colspan=&quot;3&quot; style=&quot;border-bottom:solid 1px #000000&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot;&gt;After PSM&lt;/th&gt;&lt;/tr&gt;&lt;tr style=&quot;border-bottom:solid 1px #000000&quot;&gt;&lt;th align=&quot;left&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;HR&lt;/th&gt;&lt;th align=&quot;left&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;95% CI&lt;/th&gt;&lt;th align=&quot;left&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;p&lt;/italic&gt;
&lt;/th&gt;&lt;th align=&quot;left&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;HR&lt;/th&gt;&lt;th align=&quot;left&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;95% CI&lt;/th&gt;&lt;th align=&quot;left&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;p&lt;/italic&gt;
&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody valign=&quot;top&quot;&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Thoracic tumor radiotherapy (yes vs. no)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.214&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.104â0.440&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.252&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.115â0.553&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.001&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;T1â2 vs. T3â4&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.615&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.412â0.920&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.018&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;N 0â2 vs. N3&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.688&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.475â0.996&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.047&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.548&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.356â0.845&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.007&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ALKâTKIs vs. EGFRâTKIs&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.336&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.180â0.627&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.001&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.430&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.212â0.871&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.019&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Radiotherapy (yes vs. no)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.333&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.163â0.683&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.003&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;â0.383&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.172â0.853&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.019&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>15677</offset><text>Variable	Before PSM	After PSM	 	HR	95% CI	p	HR	95% CI	p	 	Thoracic tumor radiotherapy (yes vs. no)	0.214	0.104â0.440	&lt;0.001	0.252	0.115â0.553	0.001	 	T1â2 vs. T3â4	0.615	0.412â0.920	0.018				 	N 0â2 vs. N3	0.688	0.475â0.996	0.047	0.548	0.356â0.845	0.007	 	ALKâTKIs vs. EGFRâTKIs	0.336	0.180â0.627	0.001	0.430	0.212â0.871	0.019	 	Radiotherapy (yes vs. no)	0.333	0.163â0.683	0.003	â0.383	0.172â0.853	0.019	 	</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>16114</offset><text>Lung radiation toxicity</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>16138</offset><text>The majority of lung radiation toxicities were Grade 1. From our observation, patients did not exhibit Grades 4â5 radiation toxicities. In 69 evaluable patients, the rates of Grade 3 radiation pneumonitis (RP) and esophagitis (RE) were 10.1% and 11.6%, respectively. There were 12 (17.4%) and 15 (21.7%) cases of Grade 2 RP and RE, respectively.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>16486</offset><text>DISCUSSION</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>16497</offset><text>For all we know, this is the first research to report the role of thoracic tumor radiotherapy on OS in MPEâNSCLC patients treated with targeted therapy. The clinical characteristics of these patients included male proportion of 48.6%, age â¤70âyears in majority of the patients, distant metastasis site, and T3â4 and N3 for 68.9% and 56.1% of patients, respectively, which were analogous to those reported for stage IV NSCLC without MPE. Treatment for MPEâNSCLC mainly aims at controlling MPE to improve life quality based on systematic drug treatment. However, the prognosis was poor, with the mean survival time (MST) of 4âmonths for systematic chemotherapy and 16â18âmonths for simple EGFRâTKIs. </text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>17214</offset><text>Historically, platinumâbased chemotherapy was the firstâline standard treatment for advanced NSCLC. Higginson DS et al. found that for such patients accepting systemic chemotherapy alone, large central tumor, bronchial compression, and vascular compression were related to poor OS. The predominant cause of death in advanced NSCLC is disease progression of thoracic tumor. During the past decade, several studies have demonstrated that for stage IV NSCLC without MPE, thoracic tumor radiotherapy combined with systematic drug treatment can decrease the local progression rate to 30% and significantly extend OS. Similar to outcome of platinumâbased chemotherapy, several clinical trials have demonstrated that the local failure rate in stage IV NSCLC with EGFRâM or ALKâP treated with targeted therapy alone is greater than 80%. In the era of targeted therapy, several studies have proved that thoracic tumor radiotherapy improves OS for patients with NSCLC without MPE. However, there is no evidence that thoracic tumor radiotherapy improves OS for MPEâNSCLC treated with targeted therapy.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>18317</offset><text>EGFRâTKIs has become an vital systemic treatment in patients with MPEâNSCLC on account of adenocarcinoma as the predominant pathological type, which has a high rate of EGFRâM, especially in the Asian population. Yang J et al. found that the ORRs for target lesions and MPE were 88.5% and 61.5%, respectively. Previous studies showed that for MPEâNSCLC patients treated with targeted therapy, the MST was approximately 16âmonths, in accord with survival outcomes in our study (17âmonths). Our study showed that the DRT group had significantly better OS in comparison with the D group (MST, 25âmonths versus 17âmonths, pâ=â0.001). However, our study had some unaccounted confounders, selection bias, and recall bias, which are the inevitable nature of retrospective research. PSM can reduce confounders and bias, and might make our results more reliable. FigureÂ 3 depicted that the OS outcome following PSM was similar to that before PSM (56 pairs, pâ=â0.007). The OS of MPEâNSCLC patients is short, and one of the most critical adverse factors for OS is a large lung mass. The more superior survival of the DRT group might be attributed to thoracic tumor controlled continuously, reduction in thoracic tumor failure and additional disease control after progression. As reported in previous studies, the OS outcome was in keeping with stage IV NSCLC without MPE based on multimodal treatment, including thoracic tumor radiotherapy and targeted therapy. </text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>19796</offset><text>Multivariate analysis revealed that thoracic tumor radiotherapy was independently associated with the extend of OS in such patients. Our findings recommended that the treatment pattern of EGFRâM/ALKâP MPEâNSCLC should not be restricted to a monotherapy but rather be a multimodal treatment. Overall survival may benefit from the synergistic combination of local radiotherapy and targeted therapy. Another result of the multivariate analysis was that N0â2 was closely relevant to improving OS in such patients. It indicated that early lymph node staging was associated with a good prognosis. The study by Parikh RB et al. also found that N2â3 was associated with a greater hazard of death. A retrospective study indicated that fewer metastatic lymph nodes were associated with better OS for NSCLC.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>20603</offset><text>It is acknowledged that the synergistic combination of local radiotherapy and targeted therapy for NSCLC lead to increased toxicity in comparison with monotherapy. Radiation toxicities of Grade 3 were observed in approximately 10% of patients, analogous to that of synchronous/concurrent chemoradiotherapy or EGFRâTKIs with radiotherapy in stage IV NSCLC without MPE. This reveals that radiation toxicities are acceptable in such patients, but it is essential to minimize the incidence and severity of RP as much as possible. </text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>21132</offset><text>Although the results of our study have very significant clinical implications, there are several shortcomings. First of all, the samples were all inpatients because of outpatients are not searchable through electronic medical records, which may lead to selection bias. Second of all, although this was a population study of hospitalized patients in our hospital, single institution is a disadvantage. Third of all, systematic treatment in the first line included targeted therapy (nâ=â101, 68.2%) and systematic chemotherapy (nâ=â47, 31.8%). Finally, this was a retrospective study with inevitable shortcomings despite using a PSM method. Therefore, randomized controlled trials (RCT) are necessary to validate the findings of this study.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>21879</offset><text>CONCLUSIONS</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>21891</offset><text>To date, the treatment of MPEâNSCLC has not changed over the past decades. Local treatment has always been a taboo area in MPEâNSCLC. Our results for EGFRâM or ALKâP MPEâNSCLC showed that thoracic tumor radiotherapy may be crucial factor in improving OS with acceptable toxicities. Potential biases should not be neglected: Further randomized controlled trials are necessary to confirm this result. Exploration of local treatment must be based on guidelines, with the aim of prolonging survival while maintaining quality of life.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">title_1</infon><offset>22431</offset><text>AUTHOR CONTRIBUTIONS</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>22452</offset><text> Qingsong Li: Conceptualization (equal); data curation (equal); formal analysis (equal); investigation (equal); methodology (equal); resources (equal); software (equal); validation (equal); visualization (equal); writing â original draft (equal); writing â review and editing (equal). Cheng Hu: Data curation (equal); formal analysis (equal); investigation (equal); resources (equal); validation (equal); visualization (equal); writing â original draft (equal). ShengâFa Su: Conceptualization (equal); formal analysis (equal); project administration (equal); supervision (equal); writing â review and editing (equal). Zhu Ma: Investigation (equal); methodology (equal); resources (equal). Yichao Geng: Formal analysis (equal); investigation (equal); methodology (equal); resources (equal); validation (equal). Yinxiang Hu: Data curation (equal); investigation (equal); resources (equal); supervision (equal); validation (equal). Haijie Jin: Data curation (equal); investigation (equal); resources (equal); writing â original draft (equal). Huiqin Li: Investigation (equal); resources (equal). Bing Lu: Conceptualization (equal); data curation (equal); formal analysis (equal); funding acquisition (equal); investigation (equal); methodology (equal); project administration (equal); resources (equal); software (equal); supervision (equal); validation (equal); visualization (equal); writing â review and editing (equal).</text></passage><passage><infon key="section_type">ACK_FUND</infon><infon key="type">title_1</infon><offset>23887</offset><text>FUNDING INFORMATION</text></passage><passage><infon key="section_type">ACK_FUND</infon><infon key="type">paragraph</infon><offset>23907</offset><text>Guizhou Science and Technology Plan Support Project [Qiankehe support (2019) 2795].</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>23991</offset><text>CONFLICT OF INTEREST STATEMENT</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>24022</offset><text>None.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>24028</offset><text>ETHICS STATEMENT</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>24045</offset><text>This study was reviewed by the ethical review boards in China (Ethics Committee of Affiliated Cancer Hospital of Guizhou Medical University, GuiYang, China).</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>24203</offset><text>Supporting information</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>24226</offset><text>DATA AVAILABILITY STATEMENT</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>24254</offset><text>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>24376</offset><text>REFERENCES</text></passage><passage><infon key="fpage">161</infon><infon key="issue">5</infon><infon key="lpage">165</infon><infon key="pub-id_pmid">24360987</infon><infon key="section_type">REF</infon><infon key="source">Arch Bronconeumol</infon><infon key="type">ref</infon><infon key="volume">50</infon><infon key="year">2014</infon><offset>24387</offset><text>Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses</text></passage><passage><infon key="fpage">209</infon><infon key="issue">3</infon><infon key="lpage">249</infon><infon key="pub-id_pmid">33538338</infon><infon key="section_type">REF</infon><infon key="source">CA Cancer J Clin</infon><infon key="type">ref</infon><infon key="volume">71</infon><infon key="year">2021</infon><offset>24472</offset><text>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</text></passage><passage><infon key="fpage">1098</infon><infon key="issue">12</infon><infon key="lpage">1104</infon><infon key="pub-id_pmid">25100651</infon><infon key="section_type">REF</infon><infon key="source">Thorax</infon><infon key="type">ref</infon><infon key="volume">69</infon><infon key="year">2014</infon><offset>24591</offset><text>Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score</text></passage><passage><infon key="fpage">235</infon><infon key="issue">1</infon><infon key="lpage">241</infon><infon key="pub-id_pmid">25429399</infon><infon key="section_type">REF</infon><infon key="source">Chest</infon><infon key="type">ref</infon><infon key="volume">148</infon><infon key="year">2015</infon><offset>24698</offset><text>Survival in patients with malignant pleural effusions who developed pleural infection: a retrospective case review from six UK centers</text></passage><passage><infon key="fpage">960</infon><infon key="issue">9</infon><infon key="lpage">967</infon><infon key="pub-id_pmid">24550423</infon><infon key="section_type">REF</infon><infon key="source">J Clin Oncol</infon><infon key="type">ref</infon><infon key="volume">32</infon><infon key="year">2014</infon><offset>24833</offset><text>Prognostic impact of minimal pleural effusion in nonâsmallâcell lung cancer</text></passage><passage><infon key="fpage">110</infon><infon key="pub-id_pmid">29963399</infon><infon key="section_type">REF</infon><infon key="source">J Vis Surg</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">2018</infon><offset>24913</offset><text>Treatment of malignant pleural effusion</text></passage><passage><infon key="fpage">229</infon><infon key="lpage">241</infon><infon key="pub-id_pmid">28694705</infon><infon key="section_type">REF</infon><infon key="source">Cancer Manag Res</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2017</infon><offset>24953</offset><text>Management of malignant pleural effusion: challenges and solutions</text></passage><passage><infon key="fpage">92</infon><infon key="issue">2</infon><infon key="lpage">98</infon><infon key="pub-id_pmid">11784875</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">346</infon><infon key="year">2002</infon><offset>25020</offset><text>Comparison of four chemotherapy regimens for advanced nonâsmallâcell lung cancer</text></passage><passage><infon key="fpage">5630</infon><infon key="issue">5</infon><infon key="lpage">5638</infon><infon key="pub-id_pmid">36380563</infon><infon key="section_type">REF</infon><infon key="source">Cancer Med</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2023</infon><offset>25105</offset><text>The effect of EGFRâTKIs on survival in advanced nonâsmallâcell lung cancer with EGFR mutations: a realâworld study</text></passage><passage><infon key="fpage">1497</infon><infon key="issue">11</infon><infon key="lpage">1508</infon><infon key="pub-id_pmid">27745820</infon><infon key="section_type">REF</infon><infon key="source">Lancet Oncol</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2016</infon><offset>25228</offset><text>Carboplatin and pemetrexed with or without pembrolizumab for advanced, nonâsquamous nonâsmallâcell lung cancer: a randomised, phase 2 cohort of the openâlabel KEYNOTEâ021 study</text></passage><passage><infon key="fpage">2288</infon><infon key="issue">24</infon><infon key="lpage">2301</infon><infon key="pub-id_pmid">29863955</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">378</infon><infon key="year">2018</infon><offset>25415</offset><text>Atezolizumab for firstâline treatment of metastatic nonsquamous NSCLC</text></passage><passage><infon key="fpage">301</infon><infon key="issue">5</infon><infon key="lpage">307</infon><infon key="pub-id_pmid">21789142</infon><infon key="section_type">REF</infon><infon key="source">Ther Adv Med Oncol</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">2010</infon><offset>25487</offset><text>The emerging role of epidermal growth factor receptor (EGFR) inhibitors in firstâline treatment for patients with advanced nonâsmall cell lung cancer positive for EGFR mutations</text></passage><passage><infon key="fpage">1004</infon><infon key="issue">11</infon><infon key="lpage">1012</infon><infon key="pub-id_pmid">21933749</infon><infon key="section_type">REF</infon><infon key="source">Lancet Oncol</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2011</infon><offset>25669</offset><text>Effect of crizotinib on overall survival in patients with advanced nonâsmallâcell lung cancer harbouring ALK gene rearrangement: a retrospective analysis</text></passage><passage><infon key="fpage">29</infon><infon key="issue">10089</infon><infon key="lpage">39</infon><infon key="pub-id_pmid">28501140</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">390</infon><infon key="year">2017</infon><offset>25827</offset><text>Alectinib versus crizotinib in patients with ALKâpositive nonâsmallâcell lung cancer (JâALEX): an openâlabel, randomised phase 3 trial</text></passage><passage><infon key="fpage">629</infon><infon key="issue">7</infon><infon key="lpage">640</infon><infon key="pub-id_pmid">27959700</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">376</infon><infon key="year">2017</infon><offset>25972</offset><text>Osimertinib or platinumâpemetrexed in EGFR T790Mâpositive lung cancer</text></passage><passage><infon key="fpage">i10</infon><infon key="issue">suppl_1</infon><infon key="lpage">i19</infon><infon key="pub-id_pmid">29462254</infon><infon key="section_type">REF</infon><infon key="source">Ann Oncol</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="year">2018</infon><offset>26046</offset><text>Mechanisms of acquired resistance to firstâ and secondâgeneration EGFR tyrosine kinase inhibitors</text></passage><passage><infon key="fpage">2132</infon><infon key="issue">6</infon><infon key="lpage">2176</infon><infon key="pub-id_pmid">32596830</infon><infon key="section_type">REF</infon><infon key="source">Med Res Rev</infon><infon key="type">ref</infon><infon key="volume">40</infon><infon key="year">2020</infon><offset>26148</offset><text>Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer</text></passage><passage><infon key="fpage">1601</infon><infon key="issue">11</infon><infon key="lpage">1607</infon><infon key="pub-id_pmid">26313684</infon><infon key="section_type">REF</infon><infon key="source">J Thorac Oncol</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2015</infon><offset>26306</offset><text>Pattern of failure analysis in metastatic EGFRâmutant lung cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy</text></passage><passage><infon key="fpage">109</infon><infon key="lpage">114</infon><infon key="pub-id_pmid">28625621</infon><infon key="section_type">REF</infon><infon key="source">Lung Cancer</infon><infon key="type">ref</infon><infon key="volume">108</infon><infon key="year">2017</infon><offset>26491</offset><text>Patterns of initial and intracranial failure in metastatic EGFRâmutant nonâsmall cell lung cancer treated with erlotinib</text></passage><passage><infon key="fpage">1807</infon><infon key="issue">12</infon><infon key="lpage">1814</infon><infon key="pub-id_pmid">23154552</infon><infon key="section_type">REF</infon><infon key="source">J Thorac Oncol</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2012</infon><offset>26616</offset><text>Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogeneâaddicted nonâsmallâcell lung cancer</text></passage><passage><infon key="fpage">346</infon><infon key="issue">3</infon><infon key="lpage">351</infon><infon key="pub-id_pmid">23407558</infon><infon key="section_type">REF</infon><infon key="source">J Thorac Oncol</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">2013</infon><offset>26776</offset><text>Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFRâmutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors</text></passage><passage><infon key="fpage">1672</infon><infon key="issue">12</infon><infon key="lpage">1682</infon><infon key="pub-id_pmid">27789196</infon><infon key="section_type">REF</infon><infon key="source">Lancet Oncol</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2016</infon><offset>26982</offset><text>Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic nonâsmallâcell lung cancer without progression after firstâline systemic therapy: a multicentre, randomised, controlled, phase 2 study</text></passage><passage><infon key="fpage">194</infon><infon key="lpage">200</infon><infon key="pub-id_pmid">30527187</infon><infon key="section_type">REF</infon><infon key="source">Lung Cancer</infon><infon key="type">ref</infon><infon key="volume">126</infon><infon key="year">2018</infon><offset>27227</offset><text>Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: a systematic review and metaâanalysis</text></passage><passage><infon key="fpage">67</infon><infon key="lpage">75</infon><infon key="pub-id_pmid">30885354</infon><infon key="section_type">REF</infon><infon key="source">Lung Cancer</infon><infon key="type">ref</infon><infon key="volume">130</infon><infon key="year">2019</infon><offset>27340</offset><text>Radical consolidative treatment provides a clinical benefit and longâterm survival in patients with synchronous oligometastatic nonâsmall cell lung cancer: a phase II study</text></passage><passage><infon key="fpage">266</infon><infon key="issue">1</infon><infon key="lpage">273</infon><infon key="pub-id_pmid">35666038</infon><infon key="section_type">REF</infon><infon key="source">Cancer Med</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2023</infon><offset>27517</offset><text>Radiotherapy with continued EGFRâTKIs for oligoprogressive disease in EGFRâmutated nonâsmall cell lung cancer: a realâworld study</text></passage><passage><infon key="fpage">846</infon><infon key="issue">6</infon><infon key="lpage">854</infon><infon key="pub-id_pmid">22242836</infon><infon key="section_type">REF</infon><infon key="source">Br J Clin Pharmacol</infon><infon key="type">ref</infon><infon key="volume">73</infon><infon key="year">2012</infon><offset>27655</offset><text>The use of tumour volumetrics to assess response to therapy in anticancer clinical trials</text></passage><passage><infon key="fpage">1409</infon><infon key="issue">6</infon><infon key="lpage">1418</infon><infon key="pub-id_pmid">23018906</infon><infon key="section_type">REF</infon><infon key="source">Eur Respir J</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">2013</infon><offset>27745</offset><text>Survival of lung adenocarcinoma patients with malignant pleural effusion</text></passage><passage><infon key="fpage">654</infon><infon key="issue">4</infon><infon key="lpage">659</infon><infon key="pub-id_pmid">25706291</infon><infon key="section_type">REF</infon><infon key="source">Respirology</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2015</infon><offset>27818</offset><text>Clinical features and survival of lung cancer patients with pleural effusions</text></passage><passage><infon key="elocation-id">e25748</infon><infon key="issue">19</infon><infon key="pub-id_pmid">34106603</infon><infon key="section_type">REF</infon><infon key="source">Medicine (Baltimore)</infon><infon key="type">ref</infon><infon key="volume">100</infon><infon key="year">2021</infon><offset>27896</offset><text>Clinical course of asymptomatic malignant pleural effusion in nonâsmall cell lung cancer patients: a multicenter retrospective study</text></passage><passage><infon key="fpage">304</infon><infon key="issue">4</infon><infon key="lpage">313</infon><infon key="pub-id_pmid">28124437</infon><infon key="section_type">REF</infon><infon key="source">Asia Pac J Clin Oncol</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2017</infon><offset>28031</offset><text>Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptorâmutated lung cancer receiving tyrosine kinase inhibitors as firstâline treatment</text></passage><passage><infon key="fpage">3567</infon><infon key="issue">6</infon><infon key="lpage">3571</infon><infon key="pub-id_pmid">29848711</infon><infon key="section_type">REF</infon><infon key="source">Anticancer Res</infon><infon key="type">ref</infon><infon key="volume">38</infon><infon key="year">2018</infon><offset>28231</offset><text>Impact of pleural effusion on outcomes of patients receiving Osimertinib for NSCLC harboring EGFR T790M</text></passage><passage><infon key="fpage">e385</infon><infon key="issue">3</infon><infon key="lpage">e392</infon><infon key="pub-id_pmid">22857887</infon><infon key="section_type">REF</infon><infon key="source">Int J Radiat Oncol Biol Phys</infon><infon key="type">ref</infon><infon key="volume">84</infon><infon key="year">2012</infon><offset>28335</offset><text>The impact of local and regional disease extent on overall survival in patients with advanced stage IIIB/IV nonâsmall cell lung carcinoma</text></passage><passage><infon key="fpage">166</infon><infon key="pub-id_pmid">22118497</infon><infon key="section_type">REF</infon><infon key="source">Radiat Oncol</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2011</infon><offset>28475</offset><text>Longâterm survival in patients with nonâsmall cell lung cancer and synchronous brain metastasis treated with wholeâbrain radiotherapy and thoracic chemoradiation</text></passage><passage><infon key="fpage">e61</infon><infon key="issue">1</infon><infon key="lpage">e67</infon><infon key="pub-id_pmid">22503522</infon><infon key="section_type">REF</infon><infon key="source">Int J Radiat Oncol Biol Phys</infon><infon key="type">ref</infon><infon key="volume">84</infon><infon key="year">2012</infon><offset>28643</offset><text>Prognostic impact of radiation therapy to the primary tumor in patients with nonâsmall cell lung cancer and oligometastasis at diagnosis</text></passage><passage><infon key="fpage">197</infon><infon key="issue">2</infon><infon key="lpage">203</infon><infon key="pub-id_pmid">24051084</infon><infon key="section_type">REF</infon><infon key="source">Lung Cancer</infon><infon key="type">ref</infon><infon key="volume">82</infon><infon key="year">2013</infon><offset>28782</offset><text>Is there an oligometastatic state in nonâsmall cell lung cancer? A systematic review of the literature</text></passage><passage><infon key="fpage">769</infon><infon key="issue">4</infon><infon key="lpage">777</infon><infon key="pub-id_pmid">26530745</infon><infon key="section_type">REF</infon><infon key="source">Int J Radiat Oncol Biol Phys</infon><infon key="type">ref</infon><infon key="volume">93</infon><infon key="year">2015</infon><offset>28887</offset><text>Threeâdimensional radiation therapy to the primary tumor with concurrent chemotherapy in patients with stage IV nonâsmall cell lung cancer: results of a multicenter phase 2 study from PPRAâRTOG, China</text></passage><passage><infon key="fpage">1222</infon><infon key="issue">4</infon><infon key="lpage">1239</infon><infon key="pub-id_pmid">33465302</infon><infon key="section_type">REF</infon><infon key="source">Cancer Med</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2021</infon><offset>29094</offset><text>Safety and efficacy of PDâ1/PDâL1 inhibitors combined with radiotherapy in patients with nonâsmallâcell lung cancer: a systematic review and metaâanalysis</text></passage><passage><infon key="fpage">1031</infon><infon key="lpage">e612</infon><infon key="pub-id_pmid">31040256</infon><infon key="section_type">REF</infon><infon key="source">Oncologist</infon><infon key="type">ref</infon><infon key="volume">24</infon><infon key="year">2019</infon><offset>29259</offset><text>Concurrent EGFRâTKI and thoracic radiotherapy as firstâline treatment for stage IV nonâsmall cell lung cancer harboring EGFR active mutations</text></passage><passage><infon key="fpage">37</infon><infon key="issue">1</infon><infon key="lpage">46.e7</infon><infon key="pub-id_pmid">31447303</infon><infon key="section_type">REF</infon><infon key="source">Clin Lung Cancer</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">2020</infon><offset>29407</offset><text>Improved overall survival with comprehensive local consolidative therapy in synchronous oligometastatic nonâsmallâcell lung cancer</text></passage><passage><infon key="fpage">924</infon><infon key="issue">4</infon><infon key="lpage">930</infon><infon key="pub-id_pmid">18508816</infon><infon key="section_type">REF</infon><infon key="source">Eur Respir J</infon><infon key="type">ref</infon><infon key="volume">32</infon><infon key="year">2008</infon><offset>29542</offset><text>Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma</text></passage><passage><infon key="fpage">908</infon><infon key="issue">3</infon><infon key="lpage">916</infon><infon key="pub-id_pmid">28934846</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res Treat</infon><infon key="type">ref</infon><infon key="volume">50</infon><infon key="year">2018</infon><offset>29652</offset><text>EGFR mutation status in lung adenocarcinomaâassociated malignant pleural effusion and efficacy of EGFR tyrosine kinase inhibitors</text></passage><passage><infon key="fpage">53</infon><infon key="issue">1</infon><infon key="lpage">60</infon><infon key="pub-id_pmid">30523401</infon><infon key="section_type">REF</infon><infon key="source">Lung</infon><infon key="type">ref</infon><infon key="volume">197</infon><infon key="year">2019</infon><offset>29784</offset><text>Cytotoxic natural killer subpopulations as a prognostic factor of malignant pleural effusion</text></passage><passage><infon key="fpage">1383</infon><infon key="issue">9</infon><infon key="lpage">1392</infon><infon key="pub-id_pmid">29852232</infon><infon key="section_type">REF</infon><infon key="source">J Thorac Oncol</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2018</infon><offset>29877</offset><text>Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with firstâline EGFRâTKIs</text></passage><passage><infon key="fpage">568</infon><infon key="issue">9</infon><infon key="lpage">575</infon><infon key="pub-id_pmid">28499791</infon><infon key="section_type">REF</infon><infon key="source">Clin Oncol (R Coll Radiol)</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="year">2017</infon><offset>30060</offset><text>The role of radiotherapy in epidermal growth factor receptor mutationâpositive patients with Oligoprogression: a matchedâcohort analysis</text></passage><passage><infon key="fpage">3328</infon><infon key="issue">8</infon><infon key="lpage">3335</infon><infon key="pub-id_pmid">15833866</infon><infon key="section_type">REF</infon><infon key="source">Cancer Res</infon><infon key="type">ref</infon><infon key="volume">65</infon><infon key="year">2005</infon><offset>30201</offset><text>Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva)</text></passage><passage><infon key="fpage">173</infon><infon key="issue">2</infon><infon key="lpage">181</infon><infon key="pub-id_pmid">25592111</infon><infon key="section_type">REF</infon><infon key="source">Radiother Oncol</infon><infon key="type">ref</infon><infon key="volume">114</infon><infon key="year">2015</infon><offset>30330</offset><text>Synergistic effects of crizotinib and radiotherapy in experimental EML4âALK fusion positive lung cancer</text></passage><passage><infon key="fpage">6167</infon><infon key="issue">18</infon><infon key="lpage">6188</infon><infon key="pub-id_pmid">34374490</infon><infon key="section_type">REF</infon><infon key="source">Cancer Med</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2021</infon><offset>30436</offset><text>EGFRâmutated stage IV nonâsmall cell lung cancer: what is the role of radiotherapy combined with TKI</text></passage><passage><infon key="fpage">182</infon><infon key="issue">2</infon><infon key="lpage">189</infon><infon key="pub-id_pmid">27042220</infon><infon key="section_type">REF</infon><infon key="source">Thorac Cancer</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2016</infon><offset>30541</offset><text>Radical thoracic radiotherapy may provide favorable outcomes for stage IV nonâsmall cell lung cancer</text></passage><passage><infon key="fpage">716</infon><infon key="issue">3</infon><infon key="lpage">717</infon><infon key="pub-id_pmid">25304955</infon><infon key="section_type">REF</infon><infon key="source">Int J Radiat Oncol Biol Phys</infon><infon key="type">ref</infon><infon key="volume">90</infon><infon key="year">2014</infon><offset>30644</offset><text>Definitive primary therapy in patients presenting with oligometastatic nonâsmall cell lung cancer: in regard to Parikh Palma DA</text></passage><passage><infon key="section_type">REF</infon><infon key="source">A Comparison of the Currently Used Nodal Stage Classification with the Number of Metastatic Lymph Nodes and the Number of Metastatic Lymph Node Stations for NonâSmall Cell Lung Cancer</infon><infon key="type">ref</infon><infon key="year">2019</infon><offset>30774</offset></passage><passage><infon key="fpage">456</infon><infon key="issue">4</infon><infon key="lpage">463</infon><infon key="pub-id_pmid">25646743</infon><infon key="section_type">REF</infon><infon key="source">Anticancer Drugs</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2015</infon><offset>30775</offset><text>Fullâdose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous nonâsmall cell lung cancer</text></passage><passage><infon key="fpage">189</infon><infon key="issue">2</infon><infon key="lpage">194</infon><infon key="pub-id_pmid">21247653</infon><infon key="section_type">REF</infon><infon key="source">Lung Cancer</infon><infon key="type">ref</infon><infon key="volume">73</infon><infon key="year">2011</infon><offset>30935</offset><text>Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a monoâinstitutional experience</text></passage><passage><infon key="fpage">e59</infon><infon key="issue">3</infon><infon key="lpage">e65</infon><infon key="pub-id_pmid">21345607</infon><infon key="section_type">REF</infon><infon key="source">Int J Radiat Oncol Biol Phys</infon><infon key="type">ref</infon><infon key="volume">81</infon><infon key="year">2011</infon><offset>31070</offset><text>Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic nonâsmallâcell lung cancer</text></passage><passage><infon key="fpage">882</infon><infon key="issue">6</infon><infon key="lpage">885</infon><infon key="pub-id_pmid">24828665</infon><infon key="section_type">REF</infon><infon key="source">J Thorac Oncol</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2014</infon><offset>31275</offset><text>Radiation pneumonitis in patients with nonâsmallâcell lung cancer treated with erlotinib concurrent with thoracic radiotherapy</text></passage></document>
</collection>